MarketCap
Facebook
X
Telegram
BeyondSpring ROE Ratio | BYSI
Annual ROE Ratio BeyondSpring
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.13 | 33.81 | 78.44 | 556.6 | -240.51 | -70.39 | -122.34 | 584.83 | -327.3 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 584.83 | -327.3 | 55.14 |
Quarterly ROE Ratio BeyondSpring
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.79 | 34.88 | 40.65 | 22.61 | 38.43 | 108.74 | 41.46 | -4.05 | -35.95 | -106.26 | -106.26 | -106.26 | -106.26 | -106.26 | -166.74 | -158.5 | -214.52 | -191.09 | -236.84 | -131.09 | -42.27 | 48.67 | -260.44 | -275.92 | -399.12 | -448.26 | -487.96 | -206.53 | -232.77 | -154.84 | -174.1 | -158.18 | -87.46 | - | -19.26 | - | -23.78 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 108.74 | -487.96 | -122.39 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aphria Inc.
APHA
|
-4.6 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-10.02 | - | -0.90 % | $ 104 M |  USA |
 |
Chiasma, Inc.
CHMA
|
-81.47 | - | -6.00 % | $ 238 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-39.43 | $ 3.37 | 4.66 % | $ 568 M |  Singapore |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
114.86 | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
113.28 | - | 0.38 % | $ 12.9 M |  Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
1237230757.23 | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
-258.53 | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-30.76 | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
-48.9 | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
-81.85 | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-0.97 | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
-7.84 | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
-93.87 | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
1.72 | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
17.64 | $ 928.5 | 3.77 % | $ 56.9 B |  Niderland |
 |
XBiotech
XBIT
|
-32.45 | $ 1.88 | 0.53 % | $ 57.3 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
275.73 | - | -2.54 % | $ 57.2 M | USA |
 |
Xencor
XNCR
|
-14.46 | $ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
-92.81 | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
-102.05 | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
-84.8 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
-17745.54 | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
-36.25 | $ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
-15.08 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-21.28 | - | - | $ 1.94 B | Canada |
 |
Exicure
XCUR
|
-125.98 | $ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Urovant Sciences Ltd.
UROV
|
252.98 | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-14.6 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
-109.74 | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
-56.64 | - | -4.97 % | $ 664 M | USA |
|
Yunhong International
ZGYH
|
-1.19 | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
-64.51 | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-59.46 | $ 39.02 | 3.56 % | $ 3.09 B | Canada |
 |
Leap Therapeutics
LPTX
|
3.26 | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
-85.05 | $ 29.63 | 3.1 % | $ 1.53 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-151.18 | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
30.78 | $ 12.73 | -3.67 % | $ 3.03 B | USA |
 |
Cortexyme
CRTX
|
235.15 | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
2.56 | $ 3.6 | -9.22 % | $ 789 M | Britain |
 |
Daré Bioscience
DARE
|
-471.39 | $ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
-65.79 | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-5480.55 | $ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
649.18 | $ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
36.91 | $ 15.16 | 6.76 % | $ 13 B | China |
 |
Aptorum Group Limited
APM
|
-5.9 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-38.55 | $ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
-146.12 | $ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
66.92 | $ 0.05 | -14.81 % | $ 547 | USA |
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M | Canada |